论文部分内容阅读
目的:观察常规治疗基础上丹参酮Ⅱ-A磺酸钠联合低分子肝素对原发性肾病综合征(PNS)的治疗效果及安全性。方法:将45例原发性肾病综合征患者随机分为两组,分别为常规治疗组(对照组)22例及丹参酮Ⅱ-A磺酸钠联合低分子肝素治疗组(治疗组)23例。对照组给予激素、潘生丁、利尿剂等药物治疗,治疗组在此基础上加用丹参酮Ⅱ-A磺酸钠及低分子肝素。结果:经2周治疗后,治疗组甘油三脂、胆固醇、24h尿蛋白定量、血肌酐均明显下降(P<0.05),血浆蛋白明显上升(P<0.05)。结论:在常规治疗基础上丹参酮Ⅱ-A磺酸钠联合低分子肝素治疗PNS是一种有效安全的方法。
Objective: To observe the effect and safety of tanshinone Ⅱ-A sulfonate combined with low molecular weight heparin on the treatment of primary nephrotic syndrome (PNS) based on routine treatment. Methods: Forty-five patients with primary nephrotic syndrome were randomly divided into two groups: 22 cases in the conventional treatment group (control group) and 23 cases in the tanshinone Ⅱ-A sulfonate combined with low molecular weight heparin treatment group (treatment group). The control group was given hormone, dipyridamole, diuretic and other drugs. On the basis of this, the treatment group added tanshinone Ⅱ-A sulfonate and low molecular weight heparin. Results: After 2 weeks of treatment, the triglyceride, cholesterol, 24 h urinary protein and serum creatinine in the treatment group were significantly decreased (P <0.05) and the plasma protein was significantly increased (P <0.05). Conclusion: It is an effective and safe method to treat PNS with tanshinone Ⅱ-A sulfonate combined with low molecular weight heparin on the basis of routine treatment.